F-star antibodies reaching for the sky
F-star is free to push forward with its plan to 'take antibody-based therapeutics to the next level' having secured venture capitalist backing.
F-star is free to push forward with its plan to 'take antibody-based therapeutics to the next level' having secured venture capitalist backing.
Yet another production site has fallen to the unrelenting axe of big pharma's consolidation drive as Pfizer announces that its only UK manufacturing plant is to be closed down.
Crucell, Endo Pharmaceuticals, Wyeth Pharmaceuticals and SupplyScape have all had people on the move in the world of pharmaceutical manufacturing.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
A group of Canadian scientists have developed a technique to automatically inject material such as DNA or experimental drugs into individual cells, to use in drug screening.
US-based biotech firm Biogen Idec has decided to enter the booming Indian market and establish its presence in the country.